PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a gene and cell therapy group, have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.
Financial details of the agreement are not disclosed.
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.
The programme will initially focus on CAR-T therapy and aims to develop next-generation cell therapies with significantly improved efficacy and durability.
Dr Chris Torrance, CEO, PhoreMost, said: “This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER®, offering an exciting opportunity to discover and accelerate the development of clinical stage products.
“The natural complementarity between SITESEEKER® and LentiVector® offers great promise for this and future collaborations between the two companies.”
John Dawson, CEO of Oxford Biomedica, said: “We are excited to apply this next-generation technology to our LentiVector® platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.”